AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

Chris Nemeth, 51, worked in airline logistics until he got the AstraZeneca vaccine in July 2021 and developed chronic inflammatory demyelinating polyneuropathy (CIPD) which can cause numbness ...

AstraZeneca and Honeywell are developing MDIs that will use a new propellant called HFO-1234ze, which, according to the company, has 99.9% less Global Warming Potential (GWP) than existing ...

Tampa, Fla.-based Moffitt Cancer Center and drugmaker AstraZeneca are collaborating to accelerate the development of CAR-T cell and T cell receptor therapies. "We are excited to collaborate with ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

With healthcare investors crowded into the obesity-focused drugmakers, AstraZeneca, a leader in cancer at a more reasonable ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner ...